Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|February 10, 2022
Dr. Marks on how PSMA imaging is “opening doors” in prostate cancer
Author(s)Urology Times staff
“We call this a ‘disruptive innovation,’” says Leonard S. Marks, MD.
Advertisement
In this video, Leonard S. Marks, MD, explains how the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer will affect urologists and patients alike. Marks is a deKernion Endowed Chair in Urology at the David Geffen School of Medicine at the University of California, Los Angeles.
Advertisement
Related to this article
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to VIR-5500 for mCRPC
2
FDA grants 510(k) clearance to OpenFlo urinary catheter
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
5